Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Fizazi, Karim; D. Shore, Neal; L.J. Tammela, Teuvo; Ulys, Albertas; Vjaters, Egils; Polyakov, S.; Jievaltas, Mindaugas; Luz, Murilo; Yа. Alekseev, B.; Kuss, Iris; Le Berre, Marie‐Aude; Petrenciuc, Oana; Snapir, Amir; Sarapohja, Toni; Smith, Matthew

doi:10.1056/nejmoa2001342

Public

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Published in New England Journal of Medicine • Sep 9, 2020

Authors:

Karim Fizazi

Neal D. Shore

Teuvo L.J. Tammela

Abstract

BACKGROUND: Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamid...

Subject

Medicine

Placebo

Prostate cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!